..., is commonly used to prevent chemotherapy-induced nausea and vomiting. IRRs due to palonosetron are very rare, with only two reports of anaphylactic shock due to palonosetron to date. We report a case with an IRR other than anaphylaxis. Presentation: A 75-year-old man with metastatic pancreatic cancer...

... to in the content or advertisements. Case report Pancreatic cancer Neoadjuvant chemotherapy Pancreaticoduodenectomy Transhiatal esophagectomy To ensure the long-term survival of patients with pancreatic cancer, complete extirpation of pancreatic cancer using pancreatoduodenectomy (PD) and distal...

... and chylous ascites in advanced-stage pancreatic cancer. The diagnosis was made by analysis of fluid, and management aimed to treat the underlying disease, which was cancer. The management of chylothorax and chylous ascites should combine medical treatment with dietary adjustment, including surgical treatment...

...Seong-Ryong Kim; Hyun Jung Lee; Dalyong Kim Approximately 80% of pancreatic cancer is diagnosed at an advanced stage, due to lack of or vague symptoms when the cancer is still localized, leading to a high mortality rate. Known risk factors for developing pancreatic cancer are family history...

... to have metastatic pancreatic cancer. The initial workup with brain imaging revealed multiple acute/subacute ischemic strokes and a negative cardiac assessment. Accordingly, she underwent a whole-body positron emission tomography-computed tomography which revealed a hypermetabolic mass lesion...

... diffuse intestinal pneumatosis and recurrence of ductal adenocarcinoma. We hypothesize that local pancreatic cancer recurrence may lead to gastrointestinal dysmotility with consequent increased risk for CDI. The patient had almost complete resolution of PI during the CDI treatment, thus we believe...

... pancreatic cancer, the patient underwent distal pancreatectomy and splenectomy. Macroscopic view of the resected specimen showed a presumed puncture-induced pancreatic pseudocyst adjacent to the pancreas. Pathological examination showed well-differentiated adenocarcinoma and a pseudocyst with presumed...

... to in the content or advertisements. Carboplatin Complete remission Etoposide Pancreatic cancer Small-cell carcinoma The exact incidence of PSCC is unknown. Ivanics et al. [ 1 ] reported that PSCC accounted for 0.2% of all pancreatic tumors. According to the literature, PSCC is characterized...

...Mary O’Reilly; Fergus Keane; Ray Mc Dermott We report a case of a 60-year-old male with metachronous primary malignancies, pancreatic cancer and malignant melanoma which recurred simultaneously. Both cancers were challenging to diagnose and throughout the case at different times, the presence...

...Shenthol Sasankan; Lorraine Rebuck; Gloria Darrah; Moises Harari Turquie; Ian Rabinowitz We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF...

...Yusuke Miyagawa; Masato Kitazawa; Hiroe Kitahara; Yukihiko Karasawa; Takashi Orii; Yuji Soejima We report a rare case of a patient who underwent 3 successful curative operations for the metachronous appearance of pancreatic cancer. In July 2007, a 54-year-old woman underwent pylorus-preserving...

... . Cancer facts & figures 2019 [Internet] . Atlanta: American Cancer Society ; 2019 . Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html . 2. Tempero   MA . NCCN guidelines updates: pancreatic cancer . J Natl...

... for 10 months since the initial chemotherapy. Pancreatic cancer is a rapidly growing cancer and can show early metastasis to other organs, lymph node metastasis, and peritoneal dissemination; therefore, the prognosis of pancreatic cancer is very poor. Cutaneous metastasis from pancreatic cancer is rare...

...Marie McLaughlin; Alan Christie; Anna Campbell Treatments for pancreatic cancer can have debilitating side effects including fatigue, weight loss, and cardiac toxicity, resulting in functional loss and psychological distress. Exercise has been proposed as a therapy to counteract physical...

... share two case reports of patients with pancreatic cancer who developed severe pulmonary toxicity during gemcitabine combination chemotherapy. Both cases emphasize the heightened risk of pulmonary toxicity in patients receiving gemcitabine chemotherapy combinations, and a need to be vigilant to initiate...

... to in the content or advertisements. Cancer Pancreatic cancer Pancreatic carcinoma Anaplastic pancreatic ductal carcinoma Multiple pancreatic tumors Anaplastic pancreatic ductal carcinoma is a relatively rare cancer that is classified as a type of invasive pancreatic ductal cancer. It is a highly...

...William Rainey Johnson; Brett J. Theeler; David Van Echo; Patrick Young; Mary Kwok Pancreatic cancer is the fourth leading cause of cancer-related death with a median survival of 3–11 months when metastatic. We present a patient with metastatic pancreatic cancer and an exceptional response...

... cardiac failure, when treated with gemcitabine monotherapy in the adjuvant setting for pancreatic cancers. Adjuvant chemotherapy with gemcitabine has been the standard of care for pancreatic cancer patients after successful surgery since the results of the CONKO-001 and ESPAC3 study were published...

... for this association in metastatic or unresectable disease is chemotherapy for pancreatic cancer and tyrosine kinase inhibitor for kidney cancer. We also review the appropriate literature concerning that association. [email protected] 24 10 2017 24 10 2017 27 11 2017 © 2017...

... occurring after gemcitabine plus oxaliplatin (GEMOX) chemotherapy in a patient with pancreatic cancer. A 76-year-old man received GEMOX regimen as first-line treatment for pancreatic adenocarcinoma with peritoneal dissemination. GEMOX consists of gemcitabine (1,000 mg/m 2 ) and oxaliplatin (100 mg/m 2...